Current clinical evidence demonstrates that sequenced genomes provide actionable utility today, particularly in diagnosing rare pediatric conditions and guiding targeted precision oncology treatments.
The retrieved literature contains strong empirical evidence, including meta-analyses and prospective clinical studies, showing that whole-genome and exome sequencing are actively used in clinical settings to diagnose genetic disorders, identify disease predispositions, and guide cancer treatments. No papers refute the claim, so the balance verdict is SUPPORTED.